Karla F. Meza-Sosa

Dr. Karla F. Meza-Sosa

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2023 in Nature
Verified
Journal Article
Closed access
PDF file
SSSumit Sen Santara
Sumit Sen Santara
DLDian-Jang Lee
Dian-Jang Lee
ÂCÂngela Crespo
Ângela Crespo
JHJun Jacob Hu
Jun Jacob Hu
CWCaitlin Walker
Caitlin Walker
JLJudy Lieberman
Judy Lieberman

10 April 2007 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MFMargarita Flores
Margarita Flores
LMLucía Morales
Lucía Morales
CGClaudia Gonzaga-Jauregui
Claudia Gonzaga-Jauregui
RDRocío Domínguez-Vidaña
Rocío Domínguez-Vidaña
CZCinthya Zepeda
Cinthya Zepeda
RPRafael Palacios
Rafael Palacios
Several lines of evidence suggest that reiterated sequences in the human genome are targets for nonallelic homologous recombination (NAHR), which facilitates genomic rearrangements. We have used a PCR-based approach to identify breakpoint regions of rearranged structures in the human genome. In particular, we have identified intrachromosomal identical repeats that are located in reverse orientation, which may lead to chromosomal inversions. A bioinformatic workflow pathway to select appropriate regions for analysis was developed. Three such regions overlapping with known human genes, located on chromosomes 3, 15, and 19, were analyzed. The relative proportion of wild-type to rearranged structures was determined in DNA samples from blood obtained from different, unrelated individuals. The results obtained indicate that recurrent genomic rearrangements occur at relatively high frequency in somatic cells. Interestingly, the rearrangements studied were significantly more abundant in adults than in newborn individuals, suggesting that such DNA rearrangements might start to appear during embryogenesis or fetal life and continue to accumulate after birth. The relevance of our results in regard to human genomic variation is discussed.

25 June 2014 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
PDF file
KMKarla F. Meza-Sosa
Karla F. Meza-Sosa
GPGustavo Pedraza-Alva
Gustavo Pedraza-Alva
LPLeonor Pérez-Martínez
Leonor Pérez-Martínez
Development of the central nervous system requires a precisely coordinated series of events. During embryonic development, different intra- and extracellular signals stimulate neural stem cells to become neural progenitors, which eventually irreversibly exit from the cell cycle to begin the first stage of neurogenesis. However, before this event occurs, the self-renewal and proliferative capacities of neural stem cells and neural progenitors must be tightly regulated. Accordingly, the participation of various evolutionary conserved microRNAs is key in distinct CNS developmental processes of many organisms including human, mouse, chicken, frog and zebrafish. microRNAs specifically recognize and regulate the expression of target mRNAs by sequence complementarity within the mRNAs 3’ untranslated region and importantly, a single microRNA can have several target mRNAs to regulate a process; likewise, a unique mRNA can be targeted by more than one microRNA. Thus, by regulating different target genes, microRNAs let-7, microRNA-124 and microRNA-9 have been shown to promote the differentiation of neural stem cells and neural progenitors into specific neural cell types while microRNA-134, microRNA-25 and microRNA-137 have been characterized as microRNAs that induce the proliferation of neural stem cells and neural progenitors. Here we review the mechanisms of action of these two sets of microRNAs and their functional implications during the transition from neural stem cells and neural progenitors to fully differentiated neurons. The genetic and epigenetic mechanisms that regulate the expression of these microRNAs as well as the role of the recently described natural RNA circles which act as natural microRNA sponges regulating post-transcriptional microRNA expression and function during the early stages of neurogenesis is also discussed.

15 September 2011 in Journal of Neuroscience Research
Verified
Journal Article
Closed access
PDF file
KMKarla F. Meza-Sosa
Karla F. Meza-Sosa
KFKarla F.
Karla F.
David Valle-GarciaDavid Valle-Garcia
David Valle-Garcia
GPGustavo Pedraza‐Alva
Gustavo Pedraza‐Alva
LPLeonor Pérez-Martínez
Leonor Pérez-Martínez

16 April 2015 in Immunological Reviews
Verified
Journal Article
Closed access
PDF file
MAMartin Gustavo Pedraza Alva
Martin Gustavo Pedraza Alva
LPLeonor Pérez‐Martínez
Leonor Pérez‐Martínez
LVLaura Valdez‐Hernández
Laura Valdez‐Hernández
KMKarla F. Meza-Sosa
Karla F. Meza-Sosa
MAMasami Ando‐Kuri
Masami Ando‐Kuri

24 February 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
YZYing Zhang
Ying Zhang
XXXuemei Xie
Xuemei Xie
PYPourya Naderi Yeganeh
Pourya Naderi Yeganeh
DLDian-Jang Lee
Dian-Jang Lee
David Valle-GarciaDavid Valle-Garcia
David Valle-Garcia
JLJudy Lieberman
Judy Lieberman
Significance: Immunotherapy benefits some aggressive breast cancers, but many breast tumors do not respond to checkpoint blockade. Novel strategies to increase breast cancer immunogenicity are needed to improve immunotherapy. Here, we used epithelial cell adhesion molecule (EpCAM) aptamer-linked small-interfering RNA chimeras (AsiC) to selectively knock down genes in mouse breast cancers to induce tumor neoantigens or overcome immune evasion. Individual gene knockdown markedly delayed tumor growth and enhanced antitumor immunity. Cd47 and Parp1 AsiCs outperformed anti-CD47 antibody and the PARP1 inhibitor Olaparib, respectively. Combining EpCAM-AsiCs targeting multiple pathways worked better than single agents and enhanced tumor inhibition by a checkpoint inhibitor. EpCAM-AsiCs have the potential to boost immunity to tumors that are poorly responsive to checkpoint blockade.